950 reports of this reaction
2.4% of all INSULIN GLARGINE YFGN reports
#3 most reported adverse reaction
ACUTE KIDNEY INJURY is the #3 most commonly reported adverse reaction for INSULIN GLARGINE YFGN, manufactured by Biocon Biologics Inc.. There are 950 FDA adverse event reports linking INSULIN GLARGINE YFGN to ACUTE KIDNEY INJURY. This represents approximately 2.4% of all 39,886 adverse event reports for this drug.
Patients taking INSULIN GLARGINE YFGN who experience acute kidney injury should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ACUTE KIDNEY INJURY is a less commonly reported adverse event for INSULIN GLARGINE YFGN, but still significant enough to appear in the safety profile.
In addition to acute kidney injury, the following adverse reactions have been reported for INSULIN GLARGINE YFGN:
The following drugs have also been linked to acute kidney injury in FDA adverse event reports:
ACUTE KIDNEY INJURY has been reported as an adverse event in 950 FDA reports for INSULIN GLARGINE YFGN. This does not prove causation, but indicates an association observed in post-market surveillance data.
ACUTE KIDNEY INJURY accounts for approximately 2.4% of all adverse event reports for INSULIN GLARGINE YFGN, making it one of the most commonly reported side effect.
If you experience acute kidney injury while taking INSULIN GLARGINE YFGN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.